Novartis AG NVSEF

NVSEF Company Overview

Novartis AG is a global biopharmaceutical company focused on the research, development, manufacture, and commercialization of innovative prescription medicines. The company operates primarily within the pharmaceuticals and life sciences industry, with an emphasis on patented therapies that address serious and chronic diseases. Its core revenue is driven by branded innovative medicines across therapeutic areas including cardiovascular, immunology, neuroscience, oncology, ophthalmology, and rare diseases.

Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has evolved through portfolio restructuring and divestitures to sharpen its focus on innovative medicines. A significant milestone in this evolution was the 2023 spin-off of Sandoz Group AG, its former generics and biosimilars division, resulting in Novartis becoming a pure-play innovative medicines company. The company positions itself around science-led innovation, advanced development platforms, and global scale in research and commercialization.